These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 15787825

  • 1. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM, Watier H, Paintaud G, de Muret A, Vaillant L, Machet L.
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [Abstract] [Full Text] [Related]

  • 2. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K, Prins C, Saurat JH, French LE.
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
    Lacouture ME, Baron JM, Jani AB, Laumann AE, Soltani K.
    Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
    [Abstract] [Full Text] [Related]

  • 7. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T, Miyazawa K, Okabe S, Kawakubo K, Shimamoto T, Kuriyama Y, Ito Y, Kimura Y, Ohyashiki K, Serizawa H, Iwaya K, Mukai K.
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [Abstract] [Full Text] [Related]

  • 8. [Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].
    Gamo R, Calzado L, Pinedo F, López-Estebaranz JL.
    Actas Dermosifiliogr; 2008 May; 99(4):291-6. PubMed ID: 18394405
    [Abstract] [Full Text] [Related]

  • 9. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
    Abasq C, Duval-Modeste AB, Courville P, Joly P.
    Ann Dermatol Venereol; 2008 May; 135(6-7):509-11. PubMed ID: 18598807
    [No Abstract] [Full Text] [Related]

  • 10. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
    Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R.
    Cancer; 2000 Oct 15; 89(8):1835-44. PubMed ID: 11042581
    [Abstract] [Full Text] [Related]

  • 11. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT.
    Ann Hematol; 2003 Sep 15; 82(9):585-8. PubMed ID: 12898184
    [Abstract] [Full Text] [Related]

  • 12. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
    Viguier M, Bachelez H, Brice P, Rivet J, Dubertret L.
    Ann Dermatol Venereol; 2002 Oct 15; 129(10 Pt 1):1152-5. PubMed ID: 12442128
    [Abstract] [Full Text] [Related]

  • 13. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM.
    J Cutan Pathol; 2005 Oct 15; 32(9):616-21. PubMed ID: 16176299
    [Abstract] [Full Text] [Related]

  • 14. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K.
    Gan To Kagaku Ryoho; 2002 Mar 15; 29(3):473-80. PubMed ID: 11915743
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM.
    J Immunother; 2009 Mar 15; 32(6):622-31. PubMed ID: 19483647
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
    Massengale WT, McBurney E, Gurtler J.
    J Am Acad Dermatol; 2002 Mar 15; 46(3):441-3. PubMed ID: 11862185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.